Roivant Sciences Ltd. (ROIV) is in Healthcare, Biotechnology, based in United Kingdom, listed on NasdaqGS. Market cap 24.71B USD. 52-week range 15.90 to 42.50 USD. Data as of 2026-10-09.
Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies. Its clinical product candidates include IMVT-1402, a fully human monoclonal antibody targeting FcRn in development across several IgG-mediated autoimmune indications; mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease; neonatal fragment crystallizable receptor for the ...